Janux Therapeutics, Inc.

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision-engineered immunotherapies for cancer. The company’s core programs are built around its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, which are designed to activate immune responses selectively in tumors while limiting effects on healthy tissue. Janux Therapeutics is advancing a pipeline of investigational candidates that target a range of cancers, including solid tumors and prostate cancer, and its research also extends to autoimmune disease applications. The company works through preclinical and early clinical development activities, supported by collaboration and discovery efforts, positioning it as a platform-driven biotechnology business centered on novel immune-oncology research.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. David Alan Campbell Ph.D.

Employees

113

Headquarters

San Diego, CA, United States

Website

www.januxrx.com